CADTH Canadian Drug Expert Committee final recommendation: Empagliflozin / metformin hydrochloride (Synjardy -- Boehringer Ingelheim Canada Ltd.) : indication : type 2 diabetes mellitus

The CADTH Canadian Drug Expert Committee (CDEC) recommends that empagliflozin and metformin hydrochloride (empagliflozin/metformin) fixed-dose combination (FDC) be reimbursed for patients with type 2 diabetes mellitus

Corporate Authors: CADTH Canadian Drug Expert Committee, Canadian Agency for Drugs and Technologies in Health
Format: eBook
Language:English
Published: Ottawa (ON) Canadian Agency for Drugs and Technologies in Health 2016, October 25, 2016
Series:Common drug review
Subjects:
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
LEADER 01709nam a2200361 u 4500
001 EB001865489
003 EBX01000000000000001029569
005 00000000000000.0
007 tu|||||||||||||||||||||
008 190504 r ||| eng
245 0 0 |a CADTH Canadian Drug Expert Committee final recommendation: Empagliflozin / metformin hydrochloride (Synjardy -- Boehringer Ingelheim Canada Ltd.)  |h Elektronische Ressource  |b indication : type 2 diabetes mellitus 
246 3 1 |a Empagliflozin / metformin hydrochloride (Synjardy -- Boehringer Ingelheim Canada Ltd.) 
260 |a Ottawa (ON)  |b Canadian Agency for Drugs and Technologies in Health  |c 2016, October 25, 2016 
300 |a 1 PDF file (5 pages) 
653 |a Insurance, Health, Reimbursement 
653 |a Metformin / therapeutic use 
653 |a Drug Combinations 
653 |a Canada 
653 |a Sodium-Glucose Transporter 2 Inhibitors / therapeutic use 
653 |a Metformin / economics 
653 |a Diabetes Mellitus, Type 2 / drug therapy 
653 |a Sodium-Glucose Transporter 2 Inhibitors / economics 
653 |a Drug Costs 
710 2 |a CADTH Canadian Drug Expert Committee 
710 2 |a Canadian Agency for Drugs and Technologies in Health 
041 0 7 |a eng  |2 ISO 639-2 
989 |b NCBI  |a National Center for Biotechnology Information 
490 0 |a Common drug review 
856 |u https://www.ncbi.nlm.nih.gov/books/NBK532796  |3 Volltext 
082 0 |a 610 
082 0 |a 330 
520 |a The CADTH Canadian Drug Expert Committee (CDEC) recommends that empagliflozin and metformin hydrochloride (empagliflozin/metformin) fixed-dose combination (FDC) be reimbursed for patients with type 2 diabetes mellitus